Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focusing on creating value for people living with neurology and immunology conditions.
Celebrating 90 years of innovation #UCB90
Twitter Feed
-
For clinical research to improve we need to go consistently working with patients. Read Mitch Herndon’s point of view: https://t.co/LCREO4U1qh https://t.co/C0VRwnOjKP
— UCB News (@ucb_news) 14.11.2018 -
Are you interested in clinical studies but have some difficulties with the medical jargon? We publish some of our results in easy-to-understand language. Have a look at UCB Lay Summaries #UCB90 #ClinicalStudies #InspiredByPatients https://t.co/ea54xe4GR8
— UCB News (@ucb_news) 14.11.2018 -
@producerjoe We're required to report adverse events & product complaints for UCB drugs to the health authority. Visit https://t.co/Zb7Rv0gI0p for info.
— UCB News (@ucb_news) 13.11.2018
Highlights
At UCB, we take our responsibility to the planet very seriously.
UCB Ventures, a strategic corporate venture fund established in 2017 to further strengthen UCB’s ability to create value from novel insights and technologies that can transform the lives of patients suffering from severe diseases, has announced its first direct investment.
